Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer
NEW YORK — An immunotherapy-chemoradiotherapy (CRT) combination did not boost progression-free survival (PFS) in untreated, locally advanced cervical cancer, according to CALLA trial findings. Newly diagnosed patients who received durvalumab (Imfinzi) plus standard CRT did not experience a statistically significant PFS improvement versus patients who received placebo plus CRT (hazard ratio 0.84, 95% CI 0.65-1.08, […]